Cybin Inc. Gets Australian TGA Approval for MDD Trial
Ticker: HELP · Form: 6-K · Filed: Aug 26, 2025 · CIK: 1833141
Sentiment: bullish
Topics: regulatory-approval, clinical-trial, pharmaceuticals, mental-health
TL;DR
Cybin gets green light from Australia's TGA for Phase 2 MDD trial of CYB003, starting Q4 2025.
AI Summary
Cybin Inc. filed a Form 6-K on August 26, 2025, reporting a news release dated August 26, 2025. The news release, attached as Exhibit 99.1, details Cybin's receipt of approval from the Australian Therapeutic Goods Administration (TGA) for its Phase 2 trial of CYB003, a deuterated psilocybin analog, for the treatment of major depressive disorder. The trial is expected to commence in Q4 2025.
Why It Matters
This TGA approval is a significant step for Cybin, allowing them to advance their novel psychedelic therapy for major depressive disorder into a crucial Phase 2 trial in Australia.
Risk Assessment
Risk Level: medium — Regulatory approvals and trial progress in the novel psychedelic space carry inherent risks, and the success of CYB003 is not guaranteed.
Key Numbers
- Phase 2 — Trial Phase (The trial for CYB003 in Australia is entering Phase 2.)
Key Players & Entities
- Cybin Inc. (company) — Registrant and developer of CYB003
- August 26, 2025 (date) — Date of filing and news release
- Australian Therapeutic Goods Administration (TGA) (company) — Regulatory body that approved the trial
- CYB003 (drug) — Deuterated psilocybin analog being tested
- major depressive disorder (condition) — Indication for the Phase 2 trial
- Q4 2025 (date) — Expected start of the Phase 2 trial
- Doug Drysdale (person) — Chief Executive Officer of Cybin Inc.
FAQ
What is the primary purpose of this 6-K filing?
This 6-K filing is to report a news release dated August 26, 2025, announcing Cybin Inc.'s receipt of approval from the Australian TGA for its Phase 2 trial of CYB003.
What is CYB003 and what condition is it intended to treat?
CYB003 is a deuterated psilocybin analog developed by Cybin Inc. for the treatment of major depressive disorder.
When is the Phase 2 trial for CYB003 expected to begin?
The Phase 2 trial for CYB003 is expected to commence in Q4 2025.
Which regulatory body granted the approval for the trial?
The Australian Therapeutic Goods Administration (TGA) granted the approval for the Phase 2 trial.
Who signed this Form 6-K on behalf of Cybin Inc.?
Doug Drysdale, Chief Executive Officer of Cybin Inc., signed the Form 6-K.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2025-08-26 12:19:20
Filing Documents
- cybininc-form6xk08x26x2025.htm (6-K) — 10KB
- a08-26x2025australiatgaemb.htm (EX-99.1) — 26KB
- image_0a.jpg (GRAPHIC) — 14KB
- 0001833141-25-000012.txt ( ) — 57KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date August 26, 2025 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated August 26, 2025